ANIP250117P50000
- 0.78
- 0.000.00%
ANI Pharmaceuticals Newsroom
ANI Pharmaceuticals Initiated at Outperform by Leerink Partners
ANI Pharmaceuticals Analyst Ratings
Leerink Partners Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $80
ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co.
ANI Pharmaceuticals Analyst Ratings
Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Maintains Target Price $62
Truist Financial Remains a Hold on ANI Pharmaceuticals (ANIP)
ANI Pharmaceuticals: Buy Rating Backed by Consistent Revenue Growth, Strategic Acquisitions, and Strong Market Position
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $94
Truist Financial Keeps Their Hold Rating on ANI Pharmaceuticals (ANIP)
ANI Pharmaceuticals Is Maintained at Hold by Truist Securities
Piper Sandler Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $68
Piper Sandler Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $68
ANI Pharmaceuticals Analyst Ratings
ANI Pharmaceuticals Is Maintained at Outperform by Raymond James
Raymond James Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $83
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $94
ANI Pharmaceuticals Analyst Ratings
ANI Pharmaceuticals Analyst Ratings
Truist Financial Downgrades ANI Pharmaceuticals(ANIP.US) to Hold Rating, Announces Target Price $60